Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Milrinone · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Normal saline | PLACEBO_COMPARATOR | Normal saline by inhalation over 15 min |
| Milrinone | ACTIVE_COMPARATOR | Inhaled milrinone 5 mg(as for the injectable solution) |
| Name | Type | Description |
|---|---|---|
| Milrinone | DRUG | inhaled milrinone 5 mg (as for the injectable solution) |
| Normal saline | DRUG | 5 ml normal saline by inhalation over 15 min |
Inclusion Criteria: * Adult patients scheduled for elective valvular or complex (2 or more valves or * valve and revascularization) cardiac surgery under CPB with preoperative PHT defined as mean pulmonary artery pressure (MPAP) over 30 mmHg or * systolic pulmonary artery pressure (SPAP) over 40 mm...
Milrinone is a small molecule being studied for use in Valvular Stenosis, a condition involving narrowing of heart valves. It is also being investigated for related cardiovascular conditions including Valvular Insufficiency, Pulmonary Hypertension, and Coronary Artery Disease. The drug is currently in Phase 2 clinical development.
Milrinone is a small molecule that works as a phosphodiesterase inhibitor, specifically targeting phosphodiesterase 3 (PDE3). By inhibiting this enzyme, it increases intracellular cyclic AMP levels, leading to increased cardiac contractility and vasodilation. This mechanism is relevant to its use in cardiovascular conditions such as Valvular Stenosis.
Milrinone is being developed by Stoke Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol STOK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in cardiovascular indications.
Milrinone is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its potential use in treating Valvular Stenosis and other cardiovascular conditions.
Milrinone has one completed Phase 2 clinical trial registered as NCT00819377, titled "Milrinone Inhaled in Cardiac Surgery." This randomized, double-blind, placebo-controlled trial enrolled 124 participants in Canada and studied the drug in patients with Valvular Stenosis, Valvular Insufficiency, Pulmonary Hypertension, and Coronary Artery Disease.
Milrinone is also known by its brand name Primacor. It is a phosphodiesterase inhibitor used in the management of heart failure. In the context of this development program, it is being evaluated as an inhaled formulation for cardiac surgery patients with valvular and coronary artery conditions.